Coverage of early-stage science, platform technologies, R&D innovation, and emerging companies shaping the future of medicine. From discovery breakthroughs to financing rounds and pipeline progress, this section tracks the momentum driving the biotech ecosystem.
Belgian specialty pharma gains pediatric cancer franchise and FDA priority review voucher Belgian specialty pharmaceutical company SERB Pharmaceuticals announced an all-cash $412 million acquisition of
French pharma giant expands neuroscience pipeline with Boston biotech’s microglial disease expertise Sanofi announced its intention to acquire all remaining shares of Vigil Neuroscience for
Major intellectual property resolution clears path for both companies’ mRNA pipelines GlaxoSmithKline reached a landmark settlement in its high-stakes mRNA vaccine intellectual property litigation with
Pfizer and BioNTech have reached a substantial $740 million settlement agreement with CureVac to resolve a complex patent dispute involving foundational mRNA technology that underpins
Strand Therapeutics has raised an impressive $153 million in funding to advance its pioneering programmable mRNA cancer therapy platform, with backing from pharmaceutical giants Amgen
Jazz Pharmaceuticals has achieved a groundbreaking milestone in pediatric oncology with the FDA approval of Modeyso (vorasidenib), marking the first systemic treatment specifically approved for
Strategic Leaning in a Capital-Conscious Biotech Environment Flagship Pioneering’s Alltrna has made the unusual decision to trim its workforce ahead of dosing its first patient
Key Takeaways: Neurodegenerative diseases like Alzheimer’s, Parkinson’s, and ALS remain critical unmet needs in medicine. Biotech innovations, from gene therapies to biomarkers, are paving the
Key Takeaways: AI is reshaping drug discovery, reducing timelines and costs through powerful data-driven algorithms. Tools like machine learning and predictive modeling are identifying targets
Key Takeaways: CRISPR revolutionized genome editing, but new technologies are pushing the boundaries even further. Base editing, prime editing, and epigenome editing offer improved precision
